Fanconi syndrome in an elderly patient with membranous nephropathy during treatment with the immunosuppressant mizoribine.
Drug induced
Fanconi syndrome
Immunosuppressive drugs
Membranous nephropathy
Mizoribine
Nephrotic syndrome
Journal
CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
31
03
2021
accepted:
03
06
2022
pubmed:
25
6
2022
medline:
4
2
2023
entrez:
24
6
2022
Statut:
ppublish
Résumé
We report on an 80-year-old man diagnosed with Fanconi syndrome induced by mizoribine after 4 weeks of administration to treat membranous nephropathy. Mizoribine is an oral immunosuppressant that inhibits inosine monophosphate dehydrogenase and is widely used in Japan for the treatment of autoimmune diseases and nephrotic syndrome, as well as after renal transplantation. Acquired Fanconi syndrome is often caused by drugs (antibacterial, antiviral, anticancer, and anticonvulsant drugs) and is sometimes caused by autoimmune diseases, monoclonal light chain-associated diseases, or heavy metal poisoning. In our patient, hypokalemia, hypophosphatemia, glucosuria, hypouricemia, and severe proteinuria resolved gradually after discontinuation of mizoribine administration, despite oral administration of prednisolone followed by a single intravenous injection of rituximab. The patient was ultimately diagnosed with Fanconi syndrome induced by mizoribine based on his clinical course and his typical laboratory data with the absence of proximal tubular acidosis. To our knowledge, this is the first report of Fanconi syndrome possibly induced by mizoribine. Although the precise mechanism by which mizoribine induces proximal tubular dysfunction is unknown, we suggest that nephrologists should be aware of the onset of Fanconi syndrome, a rare complication during mizoribine treatment.
Identifiants
pubmed: 35749014
doi: 10.1007/s13730-022-00715-0
pii: 10.1007/s13730-022-00715-0
pmc: PMC9243880
doi:
Substances chimiques
Immunosuppressive Agents
0
mizoribine
4JR41A10VP
Ribonucleosides
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-38Informations de copyright
© 2022. The Author(s) under exclusive licence to The Japan Society of Nephrology.
Références
Kleta R. Fanconi or not Fanconi? Lowe syndrome revisited. Clin J Am Soc Nephrol. 2008;3(5):1244–5. https://doi.org/10.2215/CJN.02880608 .
doi: 10.2215/CJN.02880608
Evans R, Zdebik A, Ciurtin C, Walsh SB. Renal involvement in primary Sjogren’s syndrome. Rheumatol (Oxf). 2015;54(9):1541–8. https://doi.org/10.1093/rheumatology/kev223 .
doi: 10.1093/rheumatology/kev223
Francois H, Mariette X. Renal involvement in primary Sjogren syndrome. Nat Rev Nephrol. 2016;12(2):82–93. https://doi.org/10.1038/nrneph.2015.174 .
doi: 10.1038/nrneph.2015.174
Lacy MQ, Gertz MA. Acquired Fanconi’s syndrome associated with monoclonal gammopathies. Hematol Oncol Clin North Am. 1999;13(6):1273–80.
doi: 10.1016/S0889-8588(05)70126-X
Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45–59. https://doi.org/10.1038/s41581-018-0077-4 .
doi: 10.1038/s41581-018-0077-4
Winch S, Lean D. Comparison of changes in metal toxicity following exposure of water with high dissolved organic carbon content to solar UV-B and UV-A Radiation. Photochem Photobiol. 2005;81(6):1469–80. https://doi.org/10.1562/2005-05-29-RA-552 .
doi: 10.1562/2005-05-29-RA-552
Barbier O, Jacquillet G, Tauc M, Cougnon M, Poujeol P. Effect of heavy metals on, and handling by, the kidney. Nephron Physiol. 2005;99(4):p105–10. https://doi.org/10.1159/000083981 .
doi: 10.1159/000083981
Isnard Bagnis C, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL. Herbs and the kidney. Am J Kidney Dis. 2004;44(1):1–11.
doi: 10.1053/j.ajkd.2004.02.009
Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi’s syndrome. Am J Kidney Dis. 2003;41(2):292–309. https://doi.org/10.1053/ajkd.2003.50037 .
doi: 10.1053/ajkd.2003.50037
Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM. 2014;107(4):261–9. https://doi.org/10.1093/qjmed/hct258 .
doi: 10.1093/qjmed/hct258
Hall AM, Unwin RJ. A case of drug-induced proximal tubular dysfunction. Clin J Am Soc Nephrol. 2019;14(9):1384–7. https://doi.org/10.2215/CJN.01430219 .
doi: 10.2215/CJN.01430219
Perrone D, Afridi F, King-Morris K, Komarla A, Kar P. Proximal renal tubular acidosis (Fanconi Syndrome) induced by apremilast: a case report. Am J Kidney Dis. 2017;70(5):729–31. https://doi.org/10.1053/j.ajkd.2017.06.021 .
doi: 10.1053/j.ajkd.2017.06.021
Heidari R, Ahmadi A, Mohammadi H, Ommati MM, Azarpira N, Niknahad H. Mitochondrial dysfunction and oxidative stress are involved in the mechanism of methotrexate-induced renal injury and electrolytes imbalance. Biomed Pharmacother. 2018;107:834–40. https://doi.org/10.1016/j.biopha.2018.08.050 .
doi: 10.1016/j.biopha.2018.08.050
Werion A, Belkhir L, Perrot M, Schmit G, Aydin S, Chen Z, et al. SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney Int. 2020;98(5):1296–307. https://doi.org/10.1016/j.kint.2020.07.019 .
doi: 10.1016/j.kint.2020.07.019
Kormann R, Jacquot A, Alla A, Corbel A, Koszutski M, Voirin P, et al. Coronavirus disease 2019: acute Fanconi syndrome precedes acute kidney injury. Clin Kidney J. 2020;13(3):362–70. https://doi.org/10.1093/ckj/sfaa109 .
doi: 10.1093/ckj/sfaa109
Takahashi N, Saeki T, Komatsuda A, Munemura C, Fukui T, Imai N, et al. Tubulointerstitial nephritis with IgM-Positive plasma cells. J Am Soc Nephrol. 2017;28(12):3688–98. https://doi.org/10.1681/ASN.2016101074 .
doi: 10.1681/ASN.2016101074
Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999;6(7):575–97.
doi: 10.2174/092986730607220401123549
Ichinose K, Origuchi T, Kawashiri SY, Iwamoto N, Fujikawa K, Aramaki T, et al. Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis. Intern Med. 2010;49(20):2211–8.
doi: 10.2169/internalmedicine.49.3810
Nishimura K, Nishino J, Kouchi A, Nakamura N, Nakajima S, Yokoe I, et al. Efficacy and safety of single-dose mizoribine for patients with rheumatoid arthritis: results at 6 months after switching from a multiple-dose regimen without a change in total daily dose. Mod Rheumatol. 2011;21(2):158–63. https://doi.org/10.1007/s10165-010-0373-8 .
doi: 10.1007/s10165-010-0373-8
Yamanaka H, Seto Y, Tanaka E, Furuya T, Nakajima A, Ikari K, et al. Management of rheumatoid arthritis: the 2012 perspective. Mod Rheumatol. 2013;23(1):1–7. https://doi.org/10.1007/s10165-012-0702-1 .
doi: 10.1007/s10165-012-0702-1
Aihara Y, Miyamae T, Ito S, Kobayashi S, Imagawa T, Mori M, et al. Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus. Pediatr Int. 2002;44(2):199–204.
doi: 10.1046/j.1328-8067.2001.01534.x
Nomura A, Shimizu H, Kishimoto M, Suyama Y, Rokutanda R, Ohara Y, et al. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis. Lupus. 2012;21(13):1444–9. https://doi.org/10.1177/0961203312458468 .
doi: 10.1177/0961203312458468
Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000;58(1):317–24. https://doi.org/10.1046/j.1523-1755.2000.00168.x .
doi: 10.1046/j.1523-1755.2000.00168.x
Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, et al. A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin Exp Nephrol. 2004;8(2):117–26. https://doi.org/10.1007/s10157-004-0276-0 .
doi: 10.1007/s10157-004-0276-0
Kaneko K, Nagaoka R, Ohtomo Y, Yamashiro Y. Mizoribine for childhood IgA nephropathy. Nephron. 1999;83(4):376–7. https://doi.org/10.1159/000045438 .
doi: 10.1159/000045438
Xing S, Yang J, Zhang X, Zhou P. Comparative efficacy and safety of mizoribine with mycophenolate mofetil for Asian renal transplantation—a meta-analysis. Clin Biochem. 2014;47(7–8):663–9. https://doi.org/10.1016/j.clinbiochem.2014.01.014 .
doi: 10.1016/j.clinbiochem.2014.01.014
Ito T, Mochizuki K, Oka T, Hanada K, Tanabe K. Study of mizoribine therapy in elderly patients with membranous nephropathy: comparison with patients not receiving mizoribine. Int Urol Nephrol. 2015;47(1):131–5. https://doi.org/10.1007/s11255-014-0850-7 .
doi: 10.1007/s11255-014-0850-7
Wang X, Song X, Liu Y, Zhang W, An W, Tu Y. Treatment of membranous nephropathy with mizoribine: a control trial. Life Sci. 2016;154:75–8. https://doi.org/10.1016/j.lfs.2016.04.012 .
doi: 10.1016/j.lfs.2016.04.012
Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, et al. Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. Clin Exp Nephrol. 2017;21(6):961–70. https://doi.org/10.1007/s10157-016-1340-2 .
doi: 10.1007/s10157-016-1340-2
Simmons CF Jr, Bogusky RT, Humes HD. Inhibitory effects of gentamicin on renal mitochondrial oxidative phosphorylation. J Pharmacol Exp Ther. 1980;214(3):709–15.
Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78(11):1171–7. https://doi.org/10.1038/ki.2010.318 .
doi: 10.1038/ki.2010.318
Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773–80. https://doi.org/10.1053/j.ajkd.2011.01.022 .
doi: 10.1053/j.ajkd.2011.01.022
Skinner R. Nephrotoxicity–what do we know and what don’t we know? J Pediatr Hematol Oncol. 2011;33(2):128–34. https://doi.org/10.1097/MPH.0b013e3181f8cac0 .
doi: 10.1097/MPH.0b013e3181f8cac0
Nissim I, Horyn O, Daikhin Y, Nissim I, Luhovyy B, Phillips PC, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006;66(15):7824–31. https://doi.org/10.1158/0008-5472.CAN-06-1043 .
doi: 10.1158/0008-5472.CAN-06-1043
Knorr M, Schaper J, Harjes M, Mayatepek E, Rosenbaum T. Fanconi syndrome caused by antiepileptic therapy with valproic Acid. Epilepsia. 2004;45(7):868–71. https://doi.org/10.1111/j.0013-9580.2004.05504.x .
doi: 10.1111/j.0013-9580.2004.05504.x
Murase J, Mizuno K, Kawai K, NIshiumi S, Kobayashi Y, Hayashi M et al. Absorption, distribution, metabolism, and excretion of bredinin in rats. Pharmacomet (Jpn). 1978;5(15):829–35.
Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59(11):841–9. https://doi.org/10.1136/ard.59.11.841 .
doi: 10.1136/ard.59.11.841
Kelly KJ, Plotkin Z, Vulgamott SL, Dagher PC. P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor. J Am Soc Nephrol. 2003;14(1):128–38. https://doi.org/10.1097/01.asn.0000040596.23073.01 .
doi: 10.1097/01.asn.0000040596.23073.01
Dagher PC. Apoptosis in ischemic renal injury: roles of GTP depletion and p53. Kidney Int. 2004;66(2):506–9. https://doi.org/10.1111/j.1523-1755.2004.761_7.x .
doi: 10.1111/j.1523-1755.2004.761_7.x
Kashoor I, Batlle D. Proximal renal tubular acidosis with and without Fanconi syndrome. Kidney Res Clin Pract. 2019;38(3):267–81. https://doi.org/10.23876/j.krcp.19.056 .
doi: 10.23876/j.krcp.19.056
Bobulescu IA, Moe OW. Na+/H+ exchangers in renal regulation of acid-base balance. Semin Nephrol. 2006;26(5):334–44. https://doi.org/10.1016/j.semnephrol.2006.07.001 .
doi: 10.1016/j.semnephrol.2006.07.001
Aalkjaer C, Frische S, Leipziger J, Nielsen S, Praetorius J. Sodium coupled bicarbonate transporters in the kidney, an update. Acta Physiol Scand. 2004;181(4):505–12. https://doi.org/10.1111/j.1365-201X.2004.01324.x .
doi: 10.1111/j.1365-201X.2004.01324.x